Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

被引：154
作者：
Enting, RH
Demopoulos, A
DeAngelis, LM
Abrey, LE
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Univ Groningen Hosp, Dept Neurol, Groningen, Netherlands
来源：
NEUROLOGY | 2004年 / 63卷 / 05期
关键词：
D O I：
10.1212/01.WNL.0000137050.43114.42
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
引用
收藏
页码：901 / 903
页数：3
相关论文
共 10 条
  • [1] Treatment for primary CNS lymphoma: The next step
    Abrey, LE
    Yahalom, J
    DeAngelis, LM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3144 - 3150
  • [2] Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma
    Arellano-Rodrigo, E
    López-Guillermo, A
    Bessell, EM
    Nomdedeu, B
    Montserrat, E
    Graus, F
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (04) : 219 - 224
  • [3] CIORDIA R, 2000, 36 ANN M AM SOC CLIN
  • [4] FIGUEROA F, 2000, 36 ANN M AM SOC CLIN
  • [5] Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
    Guha-Thakurta, N
    Damek, D
    Pollack, C
    Hochberg, FH
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1999, 43 (03) : 259 - 268
  • [6] PCV salvage chemotherapy for recurrent primary CNS lymphoma
    Herrlinger, U
    Brugger, W
    Bamberg, M
    Küker, W
    Dichgans, J
    Weller, M
    [J]. NEUROLOGY, 2000, 54 (08) : 1707 - 1708
  • [7] Rituximab dose-escalation trial in chronic lymphocytic leukemia
    O'Brien, SM
    Kantarjian, H
    Thomas, DA
    Giles, FJ
    Freireich, EJ
    Cortes, J
    Lerner, S
    Keating, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2165 - 2170
  • [8] Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: Experience with two cases and review of the literature
    Pels, H
    Schulz, H
    Schlegel, U
    Engert, A
    [J]. ONKOLOGIE, 2003, 26 (04): : 351 - 354
  • [9] RENI M, 2003, P AN M AM SOC CLIN, V22, P571
  • [10] Soussain C, 2001, J CLIN ONCOL, V19, P742, DOI 10.1200/JCO.2001.19.3.742
1